Target Validation Information
TTD ID	T44141
Target Name	Angiopoietin-1 (ANGPT1)
Type of Target	Clinical trial
Drug Potency against Target	AMG 386	Drug Info	Ki = 0.9 nM	[1]
Action against Disease Model	AMG 386	Drug Info	AMG 386 is an investigational recombinant peptide-Fc fusion protein (???eptibody??? containing a peptide sequence that binds Ang1 and Ang2. AMG 386 reduces t uMor angiogenesis by selectively neutralizing Ang1 and Ang2, thereby blocking their interaction with the Tie2 receptor. In a t uMor xenograft mouse model, systemic treatment with AMG 386 inhibited t uMor growth, with subsequent disappearance of all measurable t uMors in some of the animals and evidence of an antiangiogenic mechanism of action	[2]
References
REF 1	Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell. 2004 Nov;6(5):507-16.
REF 2	Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors. Clin Cancer Res. 2010 Jun 1;16(11):3044-56.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.